Staudt, Louis (NIH/NCI)
The so-called “Phoenix” Phase III randomized clinical trial evaluated the benefit of adding the BTK inhibitor ibrutinib to standard R-CHOP chemotherapy in patients with newly diagnosed non-GCB DLBCL.
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma
Cancer Cell Volume 39, Issue 12p1549-1654
Illustrator: Erina He